Figure 1. Samples analyzed in the present study.
| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website http://www.jocmr.org |
Original Article
Volume 11, Number 9, September 2019, pages 635-641
Change in the Antimicrobial Resistance Profile of Extended-Spectrum β-Lactamase-Producing Escherichia coli
Figures
Table
| Number of antibioticsa | Pattern ID | Antibiotics | Non-ESBL (n = 983) | ESBL (n = 320) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cephamycin | Oxacephem | Carbapenems | Aminoglycosides | Tetracycline | Fluoroquinolones | n | % | n | % | |||||
| AMK: amikacin; CMZ: cefmetazole; CPFX: ciprofloxacin; ESBL: extended-spectrum beta-lactamase; ESBL-EC: ESBL-producing Escherichia coli; FMOX: flomoxef; GM: gentamicin; IPM: imipenem; LVFX: levofloxacin; MEPM: meropenem; MINO: minocycline. aThe number of antibiotics to which Escherichia coli isolates were resistant. | ||||||||||||||
| 0 | Null | 670 | 68.2 | 24 | 7.5 | |||||||||
| Subtotal | 670 | 68.2 | 24 | 7.5 | ||||||||||
| 1 | I-a | CMZ | 5 | 0.5 | 0 | 0.0 | ||||||||
| I-b | MEPM | 1 | 0.1 | 0 | 0.0 | |||||||||
| I-c | AMK | 1 | 0.1 | 0 | 0.0 | |||||||||
| I-d | GM | 22 | 2.2 | 11 | 3.4 | |||||||||
| I-e | MINO | 34 | 3.5 | 0 | 0.0 | |||||||||
| I-f | CPFX | 5 | 0.5 | 0 | 0.0 | |||||||||
| Subtotal | 68 | 6.9 | 11 | 3.4 | ||||||||||
| 2 | II-a | CMZ | FMOX | 1 | 0.1 | 1 | 0.3 | |||||||
| II-b | CMZ | GM | 2 | 0.2 | 0 | 0.0 | ||||||||
| II-c | CMZ | MINO | 0 | 0.0 | 1 | 0.3 | ||||||||
| II-d | GM | MINO | 5 | 0.5 | 2 | 0.6 | ||||||||
| II-e | GM | CPFX | 2 | 0.2 | 1 | 0.3 | ||||||||
| II-f | MINO | CPFX | 2 | 0.2 | 0 | 0.0 | ||||||||
| II-g | MINO | LVFX | 1 | 0.1 | 0 | 0.0 | ||||||||
| II-h | CPFX | LVFX | 131 | 13.3 | 183 | 57.2 | ||||||||
| Subtotal | 144 | 14.6 | 188 | 58.8 | ||||||||||
| 3 | III-a | CMZ | FMOX | GM | 1 | 0.1 | 0 | 0.0 | ||||||
| III-b | CMZ | FMOX | LVFX | 0 | 0.0 | 1 | 0.3 | |||||||
| III-c | CMZ | CPFX | LVFX | 3 | 0.3 | 1 | 0.3 | |||||||
| III-d | FMOX | IPM | MEPM | 1 | 0.1 | 0 | 0.0 | |||||||
| III-e | IPM | CPFX | LVFX | 1 | 0.1 | 0 | 0.0 | |||||||
| III-f | AMK | CPFX | LVFX | 1 | 0.1 | 0 | 0.0 | |||||||
| III-g | GM | MINO | LVFX | 1 | 0.1 | 0 | 0.0 | |||||||
| III-h | GM | CPFX | LVFX | 55 | 5.6 | 35 | 10.9 | |||||||
| III-i | MINO | CPFX | LVFX | 23 | 2.3 | 47 | 14.7 | |||||||
| Subtotal | 86 | 8.7 | 85 | 26.6 | ||||||||||
| 4 | IV-a | CMZ | FMOX | CPFX | LVFX | 1 | 0.1 | 0 | 0.0 | |||||
| IV-b | CMZ | GM | CPFX | LVFX | 2 | 0.2 | 1 | 0.3 | ||||||
| IV-c | CMZ | MINO | CPFX | LVFX | 1 | 0.1 | 2 | 0.6 | ||||||
| IV-d | IPM | MINO | CPFX | LVFX | 1 | 0.1 | 0 | 0.0 | ||||||
| IV-e | AMK | MINO | CPFX | LVFX | 0 | 0.0 | 1 | 0.3 | ||||||
| IV-f | GM | MINO | CPFX | LVFX | 5 | 0.5 | 6 | 1.9 | ||||||
| Subtotal | 10 | 1.0 | 10 | 3.1 | ||||||||||
| 5 | V-a | CMZ | FMOX | GM | CPFX | LVFX | 2 | 0.2 | 0 | 0.0 | ||||
| V-b | CMZ | FMOX | MINO | CPFX | LVFX | 2 | 0.2 | 2 | 0.6 | |||||
| V-c | CMZ | GM | MINO | CPFX | LVFX | 1 | 0.1 | 0 | 0.0 | |||||
| Subtotal | 5 | 0.5 | 2 | 0.6 | ||||||||||
| 7 | VII | CMZ | FMOX | IPM | MEPM | GM | CPFX | LVFX | 0 | 0.0 | 1 | 0.3 | ||
| Subtotal | 0 | 0.0 | 1 | 0.3 | ||||||||||